The scientists are all professors at a prestigious university that is also an alliance partner with capabilies for conducting research. The allied pharmaceutical company is a bricks and mortar company with its own R&D facility. Should Verde spend $$ needlessly to duplicate what already exists? I think the synergy and low-cost and nimble structure of Verde's operating philosophy is what makes it so compelling. I think they are also working on an alliance(s) in Canada and that may be why Harp brought in the Chief Technology Officer. Like I said in previous post, they are in a building and growth mode and IMO they are doing it the right way.
News 
Market Data 
Discover 
